Researchers at a collaborative team including Atoosa Olfati, Naser Karimi, Elham Arkan, and Mohsen Zhaleh investigated whether encapsulating the extract of Glaucium leiocarpum, commonly known as horned poppy, into nanophytosomes could enhance its antidiabetic effects. The study, published in 3 Biotech, compared the metabolic impacts of the nanophytosomal formulation against the free extract in a streptozotocin-induced diabetic rat model.
The experimental protocol involved eight distinct groups, each containing six rats, which were treated intraperitoneally for 21 consecutive days. The primary focus of the investigation was to determine if the nanophytosomal formulation could more effectively regulate non-fasting blood glucose levels and protect renal function compared to the unencapsulated extract. The team utilized gas chromatography–mass spectrometry to perform a detailed phytochemical profiling of the Glaucium leiocarpum extract, ensuring a precise understanding of the chemical constituents being delivered via the nanophytosomes.
The results indicated that the Glaucium leiocarpum extract loaded into nanophytosomes at the maximum non-lethal dose significantly reduced non-fasting blood glucose levels to 289.33 ± 14.84 mg/dL. This reduction was statistically significant, with a p-value of less than or equal to 0.05, suggesting a meaningful impact on glycemic control. Additionally, the treatment group experienced a significant increase in body weight, rising from 270.83 ± 8.87 g to 303.67 ± 10.58 g over the course of the study.
The researchers observed that serum urea levels decreased from 95.17 ± 8.13 mg/dL in the diabetic control group to 60.17 ± 4.25 mg/dL in the group treated with the maximum dose of the nanophytosomal formulation. However, the study did not find significant differences in serum creatinine, albumin, or malondialdehyde (MDA) levels among the various experimental groups.
When comparing the two delivery methods, the nanophytosomal formulation outperformed the free Glaucium leiocarpum extract in improving metabolic parameters. Nevertheless, the authors emphasized that further studies are necessary to elucidate the underlying mechanisms responsible for these improvements. Additionally, long-term effects of the treatment require evaluation to determine its safety and efficacy over extended periods.
Subject of Research: Antidiabetic effects of nanophytosomal Glaucium leiocarpum extract in diabetic rats
Article Title: Nanophytosomal encapsulation of Glaucium leiocarpum extract improves glycemic control and renal function in a streptozotocin-induced diabetic rat model
Article References: Olfati, A., Karimi, N., Arkan, E., & Zhaleh, M. (2026). Nanophytosomal encapsulation of Glaucium leiocarpum extract improves glycemic control and renal function in a streptozotocin-induced diabetic rat model. 3 Biotech, 16(12), Article 496. https://doi.org/10.1007/s13205-026-05137-8
Image Credits: AI Generated
DOI: 10.1007/s13205-026-05137-8
Keywords: Glaucium leiocarpum, nanophytosomes, diabetes, glycemic control, renal function, streptozotocin, rat model, phytochemicals, 3 Biotech, drug delivery, Nanophytosomal, encapsulation
News Source: Gregory Coleman. (November 10, 2026). Nanophytosomes improve glycemic control in diabetic rats. Scienmag.



